TABLE 4.
Variables of study in patients under EPS in the second peak of COVID‐19 pandemic
| Variables | COVID‐19 pandemic period | Control period | Variation % | P‐value | |
|---|---|---|---|---|---|
| Number of EPS | 77 | 121 | −36 | ||
| Gender (m/f) | 37/40 | 62/59 | ‐ | 0.38 | |
| Age (mean±SD)(years) | 54.12 ± 19.66 | 52.15 ± 16.94 | ‐ | 0.45 | |
| Indication of EPS | PSVT (AVNRT, AVRT) | 39 (50.6%) | 70 (57.8%) | −44 |
0.08 |
| Atrial tachyarrhythmia (AT, AFL, AF) | 10 (12.9%) | 8 (6.6%) | +25 | ||
| Bradyarrhythmia (SAN and AVN diseases) | 12 (15.5%) | 15 (12.4%) | −20 | ||
| PVC/VT | 1 (1.3%) | 13 (10.7%) | −92 | ||
| Others | 15 (19.5%) | 15 (12.4%) | 0 | ||
AT, atrial tachycardia; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; AVNRT, atrioventricular nodal reentry tachycardia; AVRT, atrioventricular reentry tachycardia; CHB, complete heart block; EPS, electrophysiology study; PSVT, paroxysmal supraventricular tachyarrhythmia; PVC, premature ventricular contraction; SAN, sinoatrial node, VT, ventricular tachycardia.